Catalyst Pharmaceuticals (CPRX) Shareholder's Equity Growth (3y) (2013 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Catalyst Pharmaceuticals | 3.82 Bn | 3.07 Bn | 134.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 44.79% |
| Dec 31, 2025 | 47.00% |
| Sep 30, 2025 | 50.48% |
| Jun 30, 2025 | 52.56% |
| Mar 31, 2025 | 53.36% |
| Dec 31, 2024 | 52.09% |
| Sep 30, 2024 | 49.29% |
| Jun 30, 2024 | 47.69% |
| Mar 31, 2024 | 46.47% |
| Dec 31, 2023 | 31.75% |
| Sep 30, 2023 | 30.56% |
| Jun 30, 2023 | 50.00% |
| Mar 31, 2023 | 49.59% |
| Dec 31, 2022 | 50.79% |
| Sep 30, 2022 | 51.29% |
| Jun 30, 2022 | 56.18% |
| Mar 31, 2022 | 62.65% |
| Dec 31, 2021 | 59.70% |
| Sep 30, 2021 | 45.82% |
| Jun 30, 2021 | 38.54% |
| Mar 31, 2021 | 32.82% |
| Dec 31, 2020 | 27.95% |
| Sep 30, 2020 | 70.27% |
| Jun 30, 2020 | 48.48% |
| Mar 31, 2020 | 41.62% |
| Dec 31, 2019 | 30.63% |
| Sep 30, 2019 | 22.04% |
| Jun 30, 2019 | 10.96% |
| Mar 31, 2019 | 0.42% |
| Dec 31, 2018 | -2.90% |
| Sep 30, 2018 | 1.85% |
| Jun 30, 2018 | 4.21% |
| Mar 31, 2018 | 4.60% |
| Dec 31, 2017 | 31.95% |
| Sep 30, 2017 | -4.67% |
| Jun 30, 2017 | -6.22% |
| Mar 31, 2017 | 25.78% |
| Dec 31, 2016 | 22.49% |
| Sep 30, 2016 | 24.71% |
| Jun 30, 2016 | 67.58% |
| Dec 31, 2015 | 55.97% |
| Mar 31, 2015 | 190.53% |
| Dec 31, 2014 | 110.83% |
| Sep 30, 2014 | 111.42% |
| Jun 30, 2014 | 102.58% |
| Dec 31, 2013 | 57.09% |